货号 (SKU)

包装规格

是否现货

价格

数量

Ab169268-100μg

100μg

现货

Ab169268-1mg

1mg

现货

Ab169268-5mg

5mg

现货

Ab169268-10mg

10mg

期货

基本信息

产品名称	Risankizumab (anti-IL-23), 白细胞介素 23 抑制剂
别名	利散吉珠单抗 \| 利桑珠单抗（抗 IL-23）
英文别名	Recombinant Risankizumab Antibody \| Risankizumab \| Risankizumab rzaa \| BI 655066 \| Risankizumab (anti-IL-23) \| Anti-IL-23a Reference Antibody (risankizumab) \| IL 23 A antibody \| IL 23 antibody \| IL 23 subunit alpha antibody \| IL 23A antibody \| IL 23p19 an
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	IL23A
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	白细胞介素 23 抑制剂

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.1 kDa (Light Chain) & 51.0 kDa (Heavy Chain), under reducing conditions; 166.7 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1612838-76-2
分子类型	抗体

图片

SEC: Risankizumab (anti-IL-23) (Ab169268)

Risankizumab (anti-IL-23) (Ab169268) - SEC
The purity of Risankizumab (anti-IL-23) (Ab169268) is more than 95% verified by HPLC.

关联靶点（人）

IL23A Tclin 白细胞介素-23 亚基 α(Interleukin-23 subunit alpha) (0 活性数据)

点击查看靶蛋白信息： IL23A

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到4个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1012772	分析证书	24-10-23	Ab169268
ZJ24F1012763	分析证书	24-10-23	Ab169268
ZJ23F0901031	分析证书	23-09-14	Ab169268
ZJ23F0901029	分析证书	23-09-14	Ab169268

可替换产品

参考文献

1. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD et al.. (2007) Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.. Hum Genet, 122 (2): (201-6). [PMID:17587057]
2. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. (2008) Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation.. Bone Marrow Transplant, 41 (9): (821-6). [PMID:18209723]
3. McGovern D, Powrie F. (2007) The IL23 axis plays a key role in the pathogenesis of IBD.. Gut, 56 (10): (1333-6). [PMID:17872562]
4. Toussirot E. (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.. Inflamm Allergy Drug Targets, 11 (2): (159-68). [PMID:22280236]
5. Baeten DL, Kuchroo VK. (2013) How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases.. Nat Med, 19 (7): (824-5). [PMID:23836225]
6. Gaffen SL, Jain R, Garg AV, Cua DJ. (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.. Nat Rev Immunol, 14 (9): (585-600). [PMID:25145755]
7. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D et al.. (2015) Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.. J Allergy Clin Immunol, 136 (1): (116-124.e7). [PMID:25769911]
8. Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE et al.. (2015) Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.. MAbs, 7 (4): (778-91). [PMID:25905918]
9. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P et al.. (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.. Lancet, 392 (10148): (650-661). [PMID:30097359]
10. Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. (2019) Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.. Br J Dermatol, 180 (6): (1348-1351). [PMID:30632140]
11. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F et al.. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.. J Immunol, 168 (11): (5699-708). [PMID:12023369]
12. Campa M, Mansouri B, Warren R, Menter A. (2016) A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.. Dermatol Ther (Heidelb), 6 (1): (1-12). [PMID:26714681]
13. Oppmann, B B and 24 more authors.. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.. Immunity, [PMID:11114383]
14. Pirhonen, Jaana J, Matikainen, Sampsa S and Julkunen, Ilkka I.. (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:12421946]
15. Smits, Hermelijn H HH and 8 more authors.. (2004) Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development.. European journal of immunology, [PMID:15114670]
16. Schnurr, Max M and 5 more authors.. (2005) Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway.. Blood, (15): [PMID:15486065]
17. Fedele, Giorgio G and 5 more authors.. (2005) Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression.. Infection and immunity, [PMID:15731058]
18. Vanden Eijnden, Serge S, Goriely, Stanislas S, De Wit, Dominique D, Goldman, Michel M and Willems, Fabienne F.. (2006) Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns.. European journal of immunology, [PMID:16342235]
19. Piskin, Gamze G, Sylva-Steenland, Regien M R RM, Bos, Jan D JD and Teunissen, Marcel B M MB.. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:16424222]
20. Langowski, John L JL and 9 more authors.. (2006) IL-23 promotes tumour incidence and growth.. Nature, (27): [PMID:16688182]
21. Vaknin-Dembinsky, Adi A, Balashov, Konstantin K and Weiner, Howard L HL.. (2006) IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:16751425]
22. Wilson, Nicholas J NJ and 15 more authors.. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells.. Nature immunology, [PMID:17676044]
23. Lupardus, Patrick J PJ and Garcia, K Christopher KC.. (2008) The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12.. Journal of molecular biology, (17): [PMID:18680750]
24. Papp, K K and 12 more authors.. (2015) Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.. The British journal of dermatology, [PMID:26042589]
25. Bloch, Yehudi and 11 more authors.. (2018) Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.. Immunity, (16): [PMID:29287995]
26. Haugh, Isabel M; Preston, Allie K; Kivelevitch, Dario N and Menter, Alan M.. (2018) Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.. Drug design, development and therapy, [PMID:30518998]
27. Machado, Álvaro Á and Torres, Tiago T.. (2018) Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.. Psoriasis (Auckland, N.Z.), [PMID:30519540]
28. Sun, Rui and Abraham, Clara.. (2020) IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant.. Cellular and molecular gastroenterology and hepatology, [PMID:32474165]
29. Glassman, Caleb R and 10 more authors.. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells.. Cell, (18): [PMID:33606986]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Risankizumab (anti-IL-23), 白细胞介素 23 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Risankizumab (anti-IL-23), 白细胞介素 23 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器